Category: Fresenius Medical Care
Kidney dialysis specialist Fresenius Medical Care forecast strong profit growth in 2016
(Reuters) - Kidney dialysis specialist Fresenius (NYSE:FMS) forecast strong profit growth in 2016 after more modest progress this year while it cuts costs to counter pressures on payments for treatment in the United States and moves into new healthcare services.
China closes out an anti-dumoing probe into foreign dialysis kit makers including Fresenius, Nikkiso and Nipro.
Fresenius Medical Care is slated to distribute CytoSorbents' cytokine blood purification filters in several countries as part of a new strategic partnership.
UPDATED Dec. 16, 2015, with comment from CytoSorbents CEO Phillip Chan.
Fresenius Medical Care acquires Cogent Healthcare and its specialty physicians business for an unspecified amount as it looks to build a $5 billion coordinated care operation.
Economic sanctions against Russia over the Ukraine crisis prompt Fresenius to scrap a Russian joint venture.
Here's a look at some of the top legal news stories for medical device companies this week: J&J's Conor MedSystems can't slip $100M Biotronik lawsuit; Supreme Court declines review of Baxter/Fresenius patent row; Medtronic, Edwards ink $750M heart valve settlement; Pa. Supreme Court to review $28M Zimmer verdict; Laid off Italian workers sue Haemonetics.
Fresenius escapes for good a $24 million patent infringement loss to dialysis rival Baxter International after the U.S. Supreme court declines to review the case.